Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 6/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | IDE | P14735 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599925 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL14613464 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL5891326 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL17641197 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL14016216 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL16841483 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL23476650 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL22769187 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL21553555 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL771650 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HLCS 2913/4885TDP1 736/4885MEN1 593/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | HLCS 2913/4885TDP1 736/4885MEN1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.